Drug Profile
Pseudocatalase
Latest Information Update: 23 Jul 2009
Price :
$50
*
At a glance
- Originator Stiefel Laboratories
- Class Peroxidases
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Vitiligo
Most Recent Events
- 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
- 08 May 2007 Discontinued - Clinical-Phase-Unknown for Vitiligo (Topical)
- 15 Dec 2000 Investigation in Vitiligo (Topical)